POA Pharma GmbH, the privately-owned pharmaceutical sales and marketing company, has today announced the launch of PKU Easy Microtabs Plus in Germany.

PKU Easy Microtabs Plus, which are specifically for individuals with Phenylketonuria (PKU), mark POA Pharma GmbH’s entry into the inborn metabolic disease (IMD) market.

The new PKU EASY Microtabs Plus product provides a ready-to-use phenylalanine-free protein substitute in micro tablet form, enriched with (‘plus’) vitamins and minerals, which replaces the requirement for a separate vitamin and minerals supplement.

Ton Albas, Managing Director of POA Pharma GmbH, stated: “This launch brings the first of POA Pharma’s IMD products into Germany. The PKU Easy Microtabs – without micronutrients -have been available in the UK, US, and Nordics for a number of years, and we are excited to offer this improved formulation to give German patients living with PKU greater choice and support.”

Rens Reinhoudt, Managing Director of POA Pharma GmbH, added: “A special coating is applied to the product to mask taste, smell and aftertaste and the formulation is designed to result in the slow release of the amino acids. This provides individuals with PKU and their health care providers an important new option in managing their daily nutritional intake. The easy-to-take micro tablets are very well suited for use away from the home and can already be taken from the age of three onwards.”

Following the initial launch in Germany and the Nordics, POA Pharma GmbH’s parent group Galen Limited is planning a phased rollout of the product across the UK, Europe, the USA and other global regions within the next 18 months.

Speaking on the company’s latest new product launch, President and Managing Director of Galen Limited, Dr Dennise Broderick said: “PKU Easy Microtabs Plus has been developed by our team of dedicated pharmaceutical and nutritional professionals with the goal of making a real contribution to making daily lives of those affected with PKU a little easier. The release of this new product is testament to POA Pharma’s commitment of providing extraordinary service to the patients and healthcare professionals we work with every day.”

#END#

Notes to editors

About POA Pharma GmbH

POA Pharma GmbH focuses on the distribution, marketing, and commercialisation of proprietary, generic, and rare disease products, bringing German patients selected products and services of POA Pharma Scandinavia AB.

Founded in 2023, we are committed to doing all we can to improve the lives and benefit the health of all generations affected by a variety of diseases.

POA Pharma GmbH benefits from being part of the wider POA Pharma network, providing the resources to help deliver high quality products and services to German patients.

Based in Copenhagen, POA Pharma Scandinavia AB, the parent company of POA Pharma GmbH, works every day to be of value to patients with inborn metabolic diseases (IMDs) and to their caregivers, offering POA products for Phenylketonuria (PKU) as well as for several other IMDs, which are currently available in the UK, Sweden, Norway, Denmark and Finland and the USA.

POA Pharma is part of Galen Limited, a privately owned company established in 1968, with global headquarters in Craigavon, Northern Ireland, and commercial operations based in the UK, Ireland, the Nordics, Europe, and the USA. With global partners in every continent, we are positioned to distribute products worldwide.

Galen Limited was founded in Northern Ireland by the late Sir Allen McClay (d. 2010), the revered philanthropist and entrepreneur, and has since become the proud founding member of the Almac Group.

With 7000+ employees and 18 facilities globally, the Almac Group is now owned by the McClay Foundation, whose overarching aim is to make a meaningful improvement and advancement in human health.